Prosensa (Netherlands) a biotech company focused on RNA interference therapeutics for muscular dystrophies raised $18 million in Series A funding. The deal was led by Abingworth Management and Life Science Partners and were joined by return backer Medsciences Capital.
Prosensa Holding BV: Series A $18M
February 14, 2007
Leave a Comment » | 
I - Series A, R - INTERNATIONAL, X - Muscular Dystrophy | 
Permalink
Posted by arubenstein
